Anixa Biosciences Inc (ANIX) Stock Price, Quote & News

Company Profile

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged in the development of a vaccine against breast cancer; and the development of a vaccine discovery pro...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 708 9808

Website: www.anixa.com

Address:

3150 Almaden Expressway, Suite 250, San Jose, United States

SCUBus Jul. 3 at 10:10 AM

$ANIX Bullish Trend: Rising price on Rising Volume.

0 · Reply

bioinvestorrr Jul. 2 at 2:07 PM

$ANIX moving differently lately🤫

0 · Reply

SCUBus Jul. 2 at 1:09 AM

$ANIX I'm a long-term Bull on ANIX, but it will be interesting to see if this chart pattern is meaningful.

0 · Reply

larry88 Jul. 1 at 5:58 PM

$ANIX Big things coming before the holiday!

0 · Reply

GSCTrader Jun. 30 at 6:00 PM

$ANIX 3.40 first trading week of July 10th

0 · Reply

Stocktradexxx Jun. 29 at 7:56 PM

$ANIX D. Boral Capital has initiated research coverage today with buy rating and $10 price target

0 · Reply

focafoca99 Jun. 29 at 1:01 PM

$ANIX posts first Korean patent for its breast cancer vaccine, extending protection through 2040.

0 · Reply

Stock_Catcher Jun. 29 at 12:45 PM

$ANIX Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

0 · Reply

SCUBus Jun. 27 at 12:43 PM

$ANIX Perfect Bullish Technical Signal... Classic Hammer Pattern.

0 · Reply

SCUBus Jun. 27 at 10:05 AM

$ANIX [Cont'd] 8) Small market cap: ~$100 million 9) Stock chart technicals: Friday's trading was a classic Japanese candlestick "hammer" pattern on HUGE volume (6X daily). Definition of a hammer candle: "a bullish reversal pattern. It indicates that despite a sharp price drop during a trading session, aggressive buying pressure entered the market to drive the price back up and close near or above the opening price".

0 · Reply

Anixa Biosciences assumed with a Buy at D. Boral Capital

2026-06-29T12:50:17.000Z - 5 days ago

Anixa Biosciences granted first Korean patent for breast cancer vaccine

Jun 29, 2026, 8:45 AM EDT - 5 days ago

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

2026-06-26T13:15:20.000Z - 8 days ago

Anixa Biosciences reports results from two clinical-stage immunotherapy programs

Jun 26, 2026, 9:10 AM EDT - 8 days ago

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

Jun 11, 2026, 9:05 AM EDT - 23 days ago

Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

Jun 10, 2026, 7:00 AM EDT - 24 days ago

Anixa Biosciences Quarterly report: Q2 2026

Jun 4, 2026, 7:00 AM EDT - 4 weeks ago

Anixa Biosciences Slides: Corporate presentation

2026-06-01T14:17:37.000Z - 4 weeks ago

Anixa Biosciences: CIPO issues Notice of Allowance for patent

Jun 1, 2026, 9:00 AM EDT - 4 weeks ago

Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance

2026-05-11T14:20:49.000Z - 7 weeks ago

Anixa Biosciences’ lira-cel shows positive survival data in ovarian cancer

May 11, 2026, 8:55 AM EDT - 7 weeks ago

Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy

May 1, 2026, 9:15 AM EDT - 2 months ago

Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV

2026-04-29T13:17:16.000Z - 2 months ago

Anixa Biosciences awarded patent for breast cancer vaccine in Mexico

Apr 29, 2026, 9:10 AM EDT - 2 months ago

Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology

Apr 22, 2026, 8:45 AM EDT - 2 months ago

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting

Apr 14, 2026, 12:30 PM EDT - 2 months ago

Anixa Biosciences Transcript: Water Tower Research Insights Conference

Apr 14, 2026, 7:00 AM EDT - 2 months ago

Anixa Biosciences Slides: Corporate presentation

Apr 9, 2026, 9:05 AM EDT - 3 months ago

Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026

Apr 7, 2026, 8:55 AM EDT - 3 months ago

Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026

Apr 6, 2026, 9:10 AM EDT - 3 months ago

Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs

2026-04-01T12:59:01.000Z - 3 months ago

Anixa Biosciences announces agreement with Cytovance Biologics

Apr 1, 2026, 8:50 AM EDT - 3 months ago

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing

Mar 30, 2026, 9:05 AM EDT - 3 months ago

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer

Mar 12, 2026, 10:38 AM EDT - 4 months ago

Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast

Mar 10, 2026, 1:00 PM EDT - 4 months ago

Anixa Biosciences Transcript: AGM 2026

Mar 10, 2026, 1:00 PM EDT - 4 months ago

Anixa Biosciences Slides: FY 2026

Mar 10, 2026, 7:00 AM EDT - 4 months ago

Anixa Biosciences Slides: Corporate presentation

2026-03-09T12:36:09.000Z - 4 months ago

Anixa Biosciences says Korean MOIP issues Notice of Allowance for new patent

Mar 9, 2026, 8:30 AM EDT - 4 months ago

Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

Mar 9, 2026, 7:00 AM EDT - 4 months ago

Anixa Biosciences Quarterly report: Q1 2026

Mar 2, 2026, 9:10 AM EST - 4 months ago

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Feb 23, 2026, 8:55 AM EST - 4 months ago

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Feb 10, 2026, 11:00 AM EST - 5 months ago

Anixa Biosciences Transcript: Fireside chat

Feb 10, 2026, 11:00 AM EST - 5 months ago

Anixa Biosciences Press release: Fireside chat

2026-02-09T13:05:35.000Z - 5 months ago

Anixa provides update on Phase 1 ovarian cancer CAR-T clinical trial

Feb 9, 2026, 8:00 AM EST - 5 months ago

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

Feb 7, 2026, 6:00 AM EST - 5 months ago

Anixa Biosciences Slides: Corporate presentation

2026-02-02T14:10:54.000Z - 5 months ago

Anixa Biosciences receives USAN Council approval for novel CAR-T therapy name

Feb 2, 2026, 9:00 AM EST - 5 months ago

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

Jan 28, 2026, 7:00 AM EST - 5 months ago

Anixa Biosciences Proxy statement: Proxy Filing

2026-01-27T13:36:37.000Z - 5 months ago

Anixa Biosciences granted patent for breast cancer vaccine technology in Mexico

Jan 27, 2026, 8:30 AM EST - 5 months ago

Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology

Jan 21, 2026, 3:54 PM EST - 5 months ago

Water Tower Research Publishes Initiation of Coverage Report on Anixa Biosciences, Inc., “Anixa's T-Cell Innovations Show Breakthrough Potential in Solid Tumors”

Jan 16, 2026, 7:00 AM EST - 6 months ago

Anixa Biosciences Slides: Investor presentation

Jan 12, 2026, 7:00 AM EST - 6 months ago

Anixa Biosciences Annual report: Q4 2025

Dec 15, 2025, 1:00 PM EST - 7 months ago

Anixa Biosciences Transcript: Water Tower Research Fireside Chat Series

2025-12-15T13:51:02.000Z - 7 months ago

Anixa announces transfer of IND for breast cancer vaccine from Cleveland Clinic

Dec 15, 2025, 8:45 AM EST - 7 months ago

Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

2025-12-11T23:05:21.000Z - 7 months ago

Anixa Biosciences says all primary endpoints met in breast cancer vaccine trial

Dec 11, 2025, 6:02 PM EST - 7 months ago

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Dec 10, 2025, 9:00 AM EST - 7 months ago

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025

2025-11-17T13:20:42.000Z - 8 months ago

Anixa Biosciences’ CAR-T therapy granted WHO approval of non-proprietary name

Nov 17, 2025, 8:15 AM EST - 8 months ago

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

Nov 17, 2025, 7:00 AM EST - 8 months ago

Anixa Biosciences Slides: Corporate Presentation

Nov 12, 2025, 11:00 AM EST - 8 months ago

Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat

2025-11-12T14:05:48.000Z - 8 months ago

Anixa Biosciences awarded patent covering breast cancer vaccine technology

Nov 12, 2025, 9:00 AM EST - 8 months ago

Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

Nov 11, 2025, 2:00 PM EST - 8 months ago

Anixa Biosciences Transcript: Fireside Chat

Nov 10, 2025, 10:30 AM EST - 8 months ago

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025

2025-11-05T14:01:35.000Z - 8 months ago

Anixa Biosciences executes data transfer with Cleveland Clinic

Nov 5, 2025, 8:55 AM EST - 8 months ago

Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Oct 23, 2025, 8:45 AM EDT - 9 months ago

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference

2025-10-20T12:30:48.000Z - 9 months ago

Anixa awarded patent in China covering breast cancer vaccine technology

Oct 20, 2025, 8:25 AM EDT - 9 months ago

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

2025-10-07T12:35:32.000Z - 9 months ago

Anixa Biosciences completes patient visit in breast cancer vaccine trial

Oct 7, 2025, 8:30 AM EDT - 9 months ago

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

2025-09-22T12:15:34.000Z - 10 months ago

Anixa announces final results from Phase 1 trial of breast cancer vaccine

Sep 22, 2025, 8:05 AM EDT - 10 months ago

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

2025-09-10T21:30:21.000Z - 10 months ago

Anixa Biosciences files $200M mixed securities shelf

Sep 10, 2025, 8:00 AM EDT - 10 months ago

Anixa Biosciences Registration statement: Registration Filing

Sep 10, 2025, 7:00 AM EDT - 10 months ago

Anixa Biosciences Quarterly report: Q3 2025

Sep 9, 2025, 10:30 AM EDT - 10 months ago

Anixa Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 8:00 AM EDT - 10 months ago

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Sep 2, 2025, 8:54 AM EDT - 10 months ago

Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 25, 2025, 9:13 AM EDT - 11 months ago

Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 20, 2025, 8:37 AM EDT - 11 months ago

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Aug 18, 2025, 9:00 AM EDT - 11 months ago

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Aug 12, 2025, 8:05 AM EDT - 11 months ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Aug 8, 2025, 9:15 AM EDT - 11 months ago

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Aug 4, 2025, 8:45 AM EDT - 11 months ago

Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial

Jul 30, 2025, 8:15 AM EDT - 1 year ago

Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology

Jul 24, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Awarded New U.S. Patent Extending Breast Cancer Vaccine IP Protection into 2040s

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology

Jun 26, 2025, 2:00 PM EDT - 1 year ago

Anixa Biosciences Transcript: Status Update

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Initiates Dosing in Fourth Cohort in its Ovarian Cancer CAR-T Clinical Trial

Jun 20, 2025, 7:30 AM EDT - 1 year ago

Anixa Biosciences to Host an Investor Webcast on June 26, 2025

Jun 10, 2025, 7:00 AM EDT - 1 year ago

Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025

Jun 3, 2025, 7:25 AM EDT - 1 year ago

Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview

Jun 2, 2025, 7:00 AM EDT - 1 year ago

Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine

SCUBus Jul. 3 at 10:10 AM

$ANIX Bullish Trend: Rising price on Rising Volume.

0 · Reply

bioinvestorrr Jul. 2 at 2:07 PM

$ANIX moving differently lately🤫

0 · Reply

SCUBus Jul. 2 at 1:09 AM

$ANIX I'm a long-term Bull on ANIX, but it will be interesting to see if this chart pattern is meaningful.

0 · Reply

larry88 Jul. 1 at 5:58 PM

$ANIX Big things coming before the holiday!

0 · Reply

GSCTrader Jun. 30 at 6:00 PM

$ANIX 3.40 first trading week of July 10th

0 · Reply

Stocktradexxx Jun. 29 at 7:56 PM

$ANIX D. Boral Capital has initiated research coverage today with buy rating and $10 price target

0 · Reply

focafoca99 Jun. 29 at 1:01 PM

$ANIX posts first Korean patent for its breast cancer vaccine, extending protection through 2040.

0 · Reply

Stock_Catcher Jun. 29 at 12:45 PM

$ANIX Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

0 · Reply

SCUBus Jun. 27 at 12:43 PM

$ANIX Perfect Bullish Technical Signal... Classic Hammer Pattern.

0 · Reply

SCUBus Jun. 27 at 10:05 AM

0 · Reply

SCUBus Jun. 27 at 9:50 AM

$ANIX THANK YOU EVERYONE who dumped shares early Friday! It was a great opportunity for me to pick up another 5,000 shares ending up 11% on the day! This is a great stock and company. Extremely well managed: 1) No Debt (name another small biotech company with no debt). 2) Lots of cash to fund ongoing clinical studies (name another biotech company with a pile of cash). 3) Low burn rate (name another small biotech company with such a low burn rate). 4) HUGE market potential (name another small biotech company addressing such huge global market diseases like Breast cancer and Ovarian cancer, not just niche and orphan diseases). 5) Extremely safe. No negative side effects for either vaccine/treatment. 6) Entering phase II for the Breast cancer vaccine. 7) Significant personal cash investments by the Chairman and other key individuals (including just recently). Name another small biotech where key executives have invested significant amounts of their own capital.

0 · Reply

Caseyd123 Jun. 26 at 7:56 PM

$ANIX is it time?

0 · Reply

wblb Jun. 26 at 2:34 PM

$ANIX Horrific leadership is why.

0 · Reply

mru01 Jun. 26 at 2:09 PM

$ANIX why is it dropping?

0 · Reply

AlgoSlayerPMPRO Jun. 26 at 1:33 PM

$ANIX Deep red, why because you have a monster float.

0 · Reply

JLCw Jun. 26 at 1:18 PM

$ANIX Positive Phase 1 breast cancer vaccine data out this morning with all major endpoints met and immune responses observed in 74% of participants. Also reported positive survival observations from its ongoing ovarian cancer CAR-T trial. Let's see if it can reclaim $2.85 for a potential move toward $3+ today

0 · Reply

carefour Jun. 26 at 1:17 PM

$ANIX send it

1 · Reply

carefour Jun. 26 at 1:17 PM

$ANIX in

0 · Reply

premarketmaker Jun. 26 at 1:12 PM

$ANIX Positive Breast Cancer Vaccine Reports Positive Data

0 · Reply

Stock_Catcher Jun. 26 at 1:10 PM

$ANIX Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

0 · Reply

jpurr Jun. 25 at 3:52 PM

$ANIX Longest phase 1 in the history of modern health? Will phase 2 be even longer?

1 · Reply

bioinvestorrr Jun. 24 at 10:43 AM

$ANIX should be getting an update on presentation from phase 1 very soon

1 · Reply

Market Cap	111.26M
Revenue (ttm)	0.00
Net Income (ttm)	-10.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	595,400
Avg Vol	184,342
Day's Range	N/A - N/A
Shares Out	34.02M
Stochastic %K	81%
Beta	0.59
Analysts	Strong Sell
Price Target	$10.00